Ipsen, S.A. and Tercica have entered into a definitive merger agreement under which an affiliate of Ipsen will acquire all outstanding shares (approximately 43%) of Tercica for approximately $663 million in cash. This transaction, which is subject to approval by Tercica stockholders, has been approved by Tercica’s board of directors. “The combination of Ipsen’s and Tercica’s development and product portfolios provides the opportunity to create a leading global endocrin...